News

The new US patent entitled, ‘Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases,’ would provide protection until 2023. Agennix chief financial officer Torsten Hombeck said

The FDA will complete the review by July 2011, as it needs more time to investigate the data submitted by Novartis in support of QAB149 NDA. The company’s

GW Pharma and Almirall have completed European Mutual Recognition Procedure (MRP) for Sativex in the treatment of spasticity due to Multiple Sclerosis (MS). The companies have already received

GLB333 helps to rebuild the damaged tissues, reduces inflammatory conditions and help to regenerate good and healthy muscle and soft tissues. National Pharma will use the worldwide license

The randomised four-arm Phase 1/2 study was designed to compare once- and twice-daily doses of ISV-303 versus Xibrom and DuraSite (vehicle), each administered twice-daily. The trial enrolled 169

Famciclovir tablets 125mg, 250mg and 500mg are Novartis Pharmaceutical’s generic version of Famvir tablets 125mg, 250mg and 500mg. Famvir is indicated for the treatment or suppression of recurrent

The open-label, multi-centre, dose escalation trial will assess the safety and tolerability of CLT-008 in the setting of chemotherapy-induced neutropenia. The trial will enroll approximately 30 evaluable patients

Eribulin mesylate was approved by the US Food and Drug Administration (FDA) on 15 November 2010, to treat patients with metastatic breast cancer who have received at least

Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. The company has